1 / 51

Updates in Nephrotic Syndrome

Updates in Nephrotic Syndrome. Dr.Fathia Ahmed Abdel Magid Consultant Paediatrician. Nephrotic syndrome is a common manifestation of glomerular disease in children.

iolana
Download Presentation

Updates in Nephrotic Syndrome

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Updates in Nephrotic Syndrome Dr.Fathia Ahmed Abdel Magid Consultant Paediatrician

  2. Nephrotic syndrome is a common manifestation of glomerular disease in children. • Develops when an abnormality of glomerular permeability results in heavy proteinuria, hypoalbuminaemia and generalized oedema

  3. Defining features of nephrotic syndrome • Early morning urine protein/creatinine ratio > 200 mg/mmol. • This is equivalent to the classical definition of protein excretion > 40 mg/m2/hr. • Hypoalbuminaemia = plasma albumin concentration < 25 gm/L. • Oedema

  4. Histological diagnosis in children presenting with nephrotic syndrome 1) Minimal change disease (80%) : more frequent in males (3:2) Age at presentation : 2-6 yrs. Incidence of MCNS in the UK is 2-4/100000 in Caucasian children and is six times higher in children of Asian origin.

  5. Aetiology and Pathogenesis of MCNS • Remain incompletely defined • Abnormality of the negatively charged residues in the glomerular basement membrane, which normally limit the filtration of anionic plasma, proteins e.g. albumin. • There is a recognized association with atopic disease and other evidence suggests that the glomerular abnormality may be induced by a soluble mediator derived from T lymphocytes.

  6. Renal biopsy • No significant abnormality on light microscopy or immunofluorescent staining. • Electron microscopy demonstrates effacement of the foot processes of the visceral glomerular epithelial cells (podocytes). A non-specific morphological change seen in most proteinuric disorders. • MCNS responds to corticosteroid therapy and is associated with a favourable long term outcome. However, at least, 70% of patients will experience a chronic, relapsing or remitting course.

  7. Focal segmental glomerulosclerosis and mesangiocapillary glomerulonephritis account for the remaining 20% of cases of nephrotic syndrome in childhood. • Compared to MCNS, these conditions tend to occur in older children. • The majority of patients do not enter remission with standard initial steroid therapy and the prognosis is poorer.

  8. Mechanisms of oedema • Hypoalbuminaemia causes ↓ in the plasma oncotic pressure and ↑ in the passage of fluid to the interstitial compartment. • Sodium reabsorption by the distal renal tubules is enhanced in the nephrotic state  ↑expansion of the extracellular fluid volume, further exacerbating oedema.

  9. Clinical features and diagnosis Patients with typical uncomplicated nephrotic syndrome require limited initial investigations.

  10. Suggested first line investigations in nephrotic syndrome • Urine dipstick analysis (protein, blood) • Early-morning urine protein/creatinine ratio • Urine microscopy and culture • Plasma albumin, creatinine and electrolytes • Full blood count • Complement C3 and C4 levels • Varicella zoster antibody titres • Hepatitis serology (Types B and C)

  11. Atypical features of MCNS • Age <1 year or >12 years • Persistent hypertension • Gross haematuria • Renal impairment • ↓ plasma C3.

  12. Blood pressure Blood pressure readings should be interpreted with reference to appropriate centile charts.

  13. Percentile Blood Pressure Readings for Children by Age and Height Percentile (mm Hg) • Girls • Age 5th 50th 95th • Percentile Percentile Percentile • 1 101/57 104/58 107/60 • 6 108/71 111/73 114/75 • 12 120/79 123/80 126/82 • 126/83 129/84 132/86 • -------------------------------------------------------

  14. Boys Age 5th 50th 95th Percentile Percentile Percentile 1 98/55 102/53 106/59 6 109/72 114/74 117/76 12 119/79 123/81 127/83 17 132/85 136/87 140/89

  15. Children with MCNS are usually normotensive. • Hypotension is a sign of severe hyponatraemia and demands urgent attention. • Blood pressure >95th centile for age, sex and height requires careful evaluation. • Hypertension may be present in hypovolaemic children because of compensatory systemic vasoconstriction. • Hypertension in the absence of hypovolaemia is an atypical feature which needs further assessment.

  16. Patients with atypical features need further investigations e.g. - ASO titre - ANA - Anti DS DNA antibodies

  17. Management General The child’s condition remains stable  ↓ the risk of complications.

  18. Use of albumin solutions • Many specialist centres use infusions of 20% albumin solution together with diuretics to relieve severe oedema in cases refractory to other management. However, this is not recommended for general use. The acute osmotic effect of the concentrated albumin solution may mobilize large quantities of ECF into the intravascular compartment causing rapid circulatory volume expansion and acute left ventricular failure. • There is no indication for the use of 20% albumin solely to raise low plasma albumin levels.

  19. Prophylactic antibiotics • Urinary losses of immunoglobulin and complement render these children susceptible to bacterial infections e.g. peritonitis, septicaemia and cellulitis. • However, some centres use prophylactic antibiotics for children with severe oedema - oral phenoxymethyl penicillin.

  20. Immunization • Mobilization • Diet • Information for parents • Corticosteroid therapy • 60 mg/m2/day of prednisolone not exceeding a maximum of 80 mg/day for one month. • The 2nd month 40 mg/m2 on alternate day. • A longer therapy of 3 months’ duration has been advocated by a working group of the German Society of Paediatric Nephrology.

  21. A metaanalysis of six trials compared two months of prednisolone with 3 months or more. It showed that the longer duration significantly ↓ the risk of relapse at 12-24 months without an increase in adverse effects. The number of patients who became frequent relapsers and the mean relapse/patient/year were also significantly reduced.

  22. The modified ISKDC regimen consist of prednisolone 60mg/m2 (maximum of 80mg) given daily for 28 days followed by prednisolone 40 mg/m2 given on alternate days, for a total of 14 doses over 28 days given as a single dose.

  23. The term: steroid sensitive nephrotic syndrome, is used for patients with minimal change nephrotic syndrome who respond to empirical corticosteroid therapy without an underlying histological diagnosis being confirmed and also includes a small number of children with underlying non-minimal change histology. • The term: steroid resistant nephrotic syndrome refers to those patients who do not respond to a standard initial course of prednisolone.

  24. Standard definitions in monitoring of steroid sensitive nephrotic syndrome Current Paediatrics , Volume 12 Number 7 December 2002

  25. Management of relapses • Relapses can be expected in at least, 70-80 % of SSNS patients. • Patients who relapse frequently in the 1st 6 months after initial steroid response, are at the highest risk of continuing to relapse frequently over the subsequent 18 months period.

  26. Relapses should be treated only after a period of 3-5 days of proteinuria. • The standard relapse regimen consist of prednisolone 60 mg/m2 until urinary remission; followed by prednisolone 40 mg/m2 on alternate day, for 14 doses. • 50% of SSNS patients will follow a frequently relapsing or steroid dependent course

  27. Maintenance Prednisolone • In frequent relapsers, a longer course of alternate day steroid is given to patients with no evidence of steroid adverse effects. • After remission, the dose is gradually tapered to a dose in the range, 0.1–0.5 mg/kg on alternate days, for 6-12 months. • Patients on maintenance prednisolone should be seen at least, every 3 months, for side effects

  28. Some potential adverse effects of therapeutic corticosteroid • Susceptibility to infection • Mood and behavioural disturbance • Increased appetite • Weight gain and obesity • Cushingnoid appearance • Acne • Hirsutism • Cutaneous striae • Posterior subcapsular cataracts • Hypertension • Growth suppresion

  29. Steroids – adverse effects (contd) • Pubertal delay • Adrenal suppression • Impaired glucose metabolism • Dyspepsia and peptic ulceration • Acute pancreatitis • Osteoporosis • Avascular osteonecrosis • Proximal myopathy

  30. Alternative Therapies Indications for alternative immunomodulatory therapy in SSNS 1. Relapse while taking prednisolone >1 mg/kg on alternate days. 2. Relapse while taking prednisolone >0.5 mg/kg on alternate days, plus one or more of the following:

  31. (a) Unacceptable adverse effects of corticosteroid therapy (b) High risk of adverse steroid effects (e.g. boys approaching puberty; diabetic children) (c) Unusually severe relapses (hypovolaemia; thrombosis, severe sepsis; acute renal failure)

  32. Typical management strategy for steroid- sensitive nephrotic syndrome • Initial episode • Prednisolone 60 mg/m2 daily for 28 days, followed by prednisolone 40 mg/m2 on alternate days, for 14 doses over 28 days. • 2. First two relapses • Prednisolone 60mg/m2 daily until remission, followed by prednisolone 40 mg/m2 on alternate days, for 14 doses over 28 days

  33. Frequent relapses • Maintenance prednisolone: 0.1-0.5 mg/kg on alternate days for up to 12 months. • Relapse on prednisolone>0.5 mg/kg on alternate days • Levamisole 2.5 mg/kg on alternate days for up to 12 months • Relapse on prednisolone> 1 mg/kg on alternate days or relapse on prednisolone > 0.5 mg/kg on alternate days plus adverse steroid effects/other risk factors. • Cyclophosphamide 3 mg/kg daily for 8 weeks.

  34. Post-cyclophosphamide relapses • As in 2 and 3 above • Relapse on prednisolone > 0.5 mg/kg on alternate days. • Cyclosporin 2.5 mg/kg per dose, given twice per day for up to 12 months.

  35. Levamisole • Has a weak steroid sparing action • Following induction of remission with prednisolone, levamisole can be started at a dose of 2.5 mg o.d on alternate days; then prednisolone can be tapered or discontinued. • It is continued for a period of 12 months after a successful remission.

  36. Levamisole (contd) • It may cause neutropenia. Therefore, a full blood count should be checked at 6 weeks, 12 weeks and every 3 months thereafter

  37. Alkylating agents • 1. Cyclophosphamide • It has the ability to induce long term remission or • cause a reduction in relapse frequency. • Dose is 3 mg/kg for an 8-week course. • Frequent relapsers have a better outcome than • those who are steroid dependent. • 70% of patients with frequently relapsing SSNS • will remain in remission after 2 years, compared • with only 25% of children with steroid dependant • NS. • Side effects include, bone marrow suppression, • neutropenia, alopecia, haemorrhagic cystitis, • gonadal toxicity (> male), malignancy. • 2. Cyclosporin

  38. The outcome of treatment of steroid sensitive nephrotic syndrome patients with levamisole (Lev) and cyclophosphamide(Cy) Suleimania Children’s Hospital, Riyadh, K.S.A. SR: Sustained remission, FRNS: frequently relapsing nephrotic syndrome, SDNS: steroid dependent nephrotic patients. Source: Saudi Journal of Kidney Diseases and Transplantation Volume 14 Number 2; June 2003

  39. Indications for referral of nephrotic patients to a paediatric nephrologist • Atypical features at initial presentation • Acute complications • Steroid-resistant nephrotic syndrome • Frequent relapses or steroid dependency in • steroid-sensitive nephrotic syndrome • Adverse effects of corticosteroid therapy and • consideration of alternative medication

  40. Nephrotic syndrome - Acute complications • Hypovolaemia • Infection • Thrombosis • Urinary losses of antithrombin III, raised plasma fibrinogen concentration and hypovolaemia contribute to a risk of vascular thrombosis in nephrotic syndrome. • Avoid blood sampling from the femoral vessels.

  41. Long term prognosis of SSNS • Is generally good • The rate of relapse will decrease over the course of several years till entering long term remission before adulthood. • Up to 20% of patients continue to have relapses till the 2nd decade of life. • After a 5-year interval of remission, approximately 20% of patients will relapse within the subsequent 5 years. • However, if a 10-year remission has been achieved, the risk of subsequent relapse is very small.

  42. NS - Mortality • Mortality rate which is about 1.7-2% is mainly due to the acute complications e.g. sepsis, vascular thrombosis, etc. • Mortality nowadays is thought to be lower.

  43. Congenital Nephrotic Syndrome • It is an uncommon disorder that may be caused by several diseases. These may be inherited, sporadic, acquired, or part of a general malformation syndrome. • In the 1st 6 months of life, causes include congenital infection and diffuse mesangeal sclerosis. • Nephrosis during the 2nd half of the 1st year is most commonly associated with idiopathic nephrotic syndrome or drugs. • Congenital nephrotic syndrome of the finish type is an autosomal recessive disease.

  44. It is caused by mutations in the gene NPHs1 which is located in the 13.1 region of the long arm of chromosome 19. • This gene codes for a cell adhesion protein called Nephrin which is synthesized by podocytes. • All children with nephrotic syndrome in the 1st year of life should have a renal biopsy.

  45. Clinical Features in 30 Children with Congenital Nephrotic Syndrome Journal of Nephrology – Jordan University Hospital

  46. OUTCOME IN 30 CHILDREN WITH CONGENITAL NEPHROTIC SYNDROME Journal of Nephrology – Jordan University Hospital

More Related